Ebrotidine is a new H2-receptor antagonist which exhibits a remarkable ability for gastric mucosal protection. A preliminary metabolic pathway for this compound was proposed and the hypothetic metabolites were synthesized. The presence of ebrotidine and its metabolites ebrotidine S-oxide and 4-bromobenzenesulfonamide in human urine has been confirmed by HPLC separation and spectroscopic characterization of the collected fractions by FT-IR and 1H NMR. Ebrotidine S,S-dioxide has been identified by HPLC using diode-array detection.
